33
Views
24
CrossRef citations to date
0
Altmetric
Original Article

The Clinicopathological Features of Anaplastic Large Cell Lymphomas Expressing p80NPM/ALK

&
Pages 25-32 | Received 25 Dec 1995, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sara Pilotto, Umberto Peretti, Silvia Novello, Giulio Rossi, Michele Milella, Matteo Giaj Levra, Ludovica Ciuffreda, Francesco Massari, Matteo Brunelli, Giampaolo Tortora & Emilio Bria. (2013) PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine . Expert Opinion on Pharmacotherapy 14:5, pages 597-608.
Read now

Articles from other publishers (23)

A. A. Paichadze, L. V. Bolotina, E. Y. Karpenko, T. V. Ustinova, A. L. Kornietskaya, A. D. Kaprin & A. A. Fedenko. (2020) EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER. Siberian journal of oncology 19:1, pages 141-146.
Crossref
Xiaoming Xing & Andrew L. Feldman. (2015) Anaplastic Large Cell Lymphomas. Advances in Anatomic Pathology 22:1, pages 29-49.
Crossref
Zhaolin Xu. 2014. Cancer Genomics. Cancer Genomics 193 211 .
Karen Pulford. 2015. Molecular Oncology. Molecular Oncology 162 189 .
Luca Mologni & Carlo Gambacorti-Passerini. (2012) New developments in the treatment of ALK-driven malignancies. Clinical Investigation 2:8, pages 835-852.
Crossref
Giorgio Scagliotti, Rolf A. Stahel, Rafael Rosell, Nick Thatcher & Jean-Charles Soria. (2012) ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development. European Journal of Cancer 48:7, pages 961-973.
Crossref
Yung-Jue Bang. (2011) The potential for crizotinib in non-small cell lung cancer: a perspective review. Therapeutic Advances in Medical Oncology 3:6, pages 279-291.
Crossref
Tony S. K. Mok. (2011) Personalized medicine in lung cancer: what we need to know. Nature Reviews Clinical Oncology 8:11, pages 661-668.
Crossref
Christopher D. O. Cooper, Charles H. Lawrie, Amanda P. Liggins, Graham P. Collins, Christian S. R. Hatton, Karen Pulford & Alison H. Banham. (2011) Identification and Characterization of Peripheral T-Cell Lymphoma-Associated SEREX Antigens. PLoS ONE 6:8, pages e23916.
Crossref
Chaim B. Colen, Mahmoud Rayes, William J. Kupsky & Murali Guthikonda. (2009) Synchronous meningioma and anaplastic large cell lymphoma. Neuropathology 30:3, pages 260-266.
Crossref
Olga K Weinberg, Katie Seo & Daniel A Arber. (2008) Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?. Human Pathology 39:9, pages 1331-1340.
Crossref
Rongshi Li & Stephan W. Morris. (2007) Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy. Medicinal Research Reviews 28:3, pages 372-412.
Crossref
Claudia Droc, Hernani D. Cualing & Marshall E. Kadin. (2017) Need for an Improved Molecular/Genetic Classification for CD30+ Lymphomas Involving the Skin. Cancer Control 14:2, pages 124-132.
Crossref
Ioannis Anagnostopoulos. 2007. Targeted Therapies in Cancer. Targeted Therapies in Cancer 177 188 .
K. Pulford, S.W. Morris & F. Turturro. (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. Journal of Cellular Physiology 199:3, pages 330-358.
Crossref
Marshall E. Kadin & Christopher Carpenter. (2003) Systemic and primary cutaneous anaplastic large cell lymphomas. Seminars in Hematology 40:3, pages 244-256.
Crossref
Brunangelo FaliniDavid Y. Mason. (2002) Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood 99:2, pages 409-426.
Crossref
Justus Duyster, Ren-Yuan Bai & Stephan W Morris. (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:40, pages 5623-5637.
Crossref
Elaine S Jaffe. (2001) Anaplastic Large Cell Lymphoma: The Shifting Sands of Diagnostic Hematopathology. Modern Pathology 14:3, pages 219-228.
Crossref
HG Drexler, SM Gignac, R von Wasielewski, M Werner & WG Dirks. (2000) Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14:9, pages 1533-1559.
Crossref
Eugenia Haralambieva, Karen A. F. Pulford, Laurence Lamant, Stefano Pileri, Giovanna Roncador, Kevin C. Gatter, Georges Delsol & David Y. Mason. (2001) Anaplastic large‐cell lymphomas of B‐cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B‐cell lymphomas. British Journal of Haematology 109:3, pages 584-591.
Crossref
Randy D. GascoynePatricia AounDaniel WuMukesh ChhanabhaiBrian F. SkinniderTimothy C. GreinerStephan W. MorrisJoseph M. ConnorsJulie M. VoseDavid S. ViswanathaAndrew ColdmanDennis D. Weisenburger. (1999) Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. Blood 93:11, pages 3913-3921.
Crossref
K.A. MacLennan & J. Diebold. (1998) Anaplastic large cell lymphoma. Current Diagnostic Pathology 5:4, pages 165-173.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.